Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study

Arnulf Stenzl,Curtis Dunshee,Ugo De Giorgi,Boris Alekseev,Taro Iguchi,Russell Z Szmulewitz,Thomas W Flaig,Bertrand Tombal,Robert Morlock,Cristina Ivanescu,Krishnan Ramaswamy, Fred Saad,Andrew J Armstrong

European Urology（2020）

引用 32|浏览59

暂无评分

摘要

Addition of enzalutamide to androgen deprivation therapy enables men with metastatic hormone-sensitive prostate cancer to maintain their high-functioning health-related quality of life and low symptom burden.

查看译文

关键词

ARCHES,Enzalutamide,Prostate cancer,Metastatic hormone-sensitive,Patient-reported outcomes,Pain

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要